Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

Thomas Metzner 1,2,*, Deborah R. Leitner 3, Karin Mellitzer 3, Andrea Beck 3, Harald Sourij 3,*, Tatjana Stojakovic 4, Gernot Reishofer 5, Winfried März 6,7,8, Ulf Landmesser 9, Hubert Scharnagl 8,*, Hermann Toplak 3,5,6,7,8 and Günther Silbernagel 1

Abstract: Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were two visits at the study site: the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Fat-tolerance tests, nuclear magnetic resonance spectroscopy, and enzyme-linked immunosorbent assays were performed to analyze lipid metabolism. Results: A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol. All of them had atherosclerotic vascular disease. There was no significant effect of alirocumab treatment on fasting triglycerides, post-prandial triglycerides, or lipoprotein-lipase regulating proteins. Total, large, and small LDL particle concentrations decreased, while the HDL particle concentration increased (all p < 0.001). Mean total circulating PCSK9 markedly increased in response to alirocumab treatment (p < 0.001). Whereas PCSK9 increased more than three-fold in all 19 compliant patients, it remained unchanged in those two patients with two injections only. Conclusion: Significant effects of alirocumab on triglyceride metabolism were not detectable in the ALIROCKS trial. The total circulating PCSK9 concentration might be a useful biomarker to differentiate non-adherence from non-response to PCSK9 antibodies.

Keywords: alirocumab; PCSK9; lipids; nuclear magnetic resonance spectroscopy; fat-tolerance test
1. Introduction

Low-density lipoprotein (LDL) cholesterol causes atherosclerotic cardiovascular disease [1]. The magnitude of life-long LDL cholesterol exposure is a major determinant of individual cardiovascular risk [2]. The earlier and more strongly the LDL cholesterol level is reduced, the greater the reduction in cardiovascular risk [3]. However, despite substantial reductions in LDL cholesterol with statins and newer lipid-lowering agents, patients continue to experience recurrent major cardiovascular events [4].

Accumulating evidence supports the relevance of triglyceride-rich lipoproteins in the management of cardiovascular disease [5,6]. Elevations of circulating triglyceride-rich lipoproteins are the result of their overproduction in the liver and/or their reduced clearance from the circulation [7]. As apolipoprotein B (ApoB)-containing lipoproteins, they carry considerable amounts of cholesterol and can enter the subintimal space, especially as remnants after the hydrolysis of triglycerides by lipoprotein lipase [5,6]. The subintimal deposition of cholesterol then leads to atherosclerotic plaques [1]. Fibrates, which reduce triglyceride-rich lipoproteins via activation of peroxisome proliferator activated receptor α, have been effective in reducing cardiovascular risk in patients with high triglycerides [8]. Accordingly, the REDUCE-IT trial showed that treatment with icosapent-ethyl, an omega-3 fatty acid, significantly reduced triglycerides and cardiovascular events [9]. Further clinical trials evaluating the safety and efficacy of medical therapies that target key regulators of triglyceride-rich lipoprotein metabolism are currently ongoing [10–12]. These key regulators include apolipoprotein C-III (ApoCIII), a potent inhibitor of lipoprotein lipase, and its antagonist apolipoprotein C-II (ApoCII) [11,13]. Angiopoietin-like proteins 3 and 4 (ANGPTL-3/4) inhibit lipoprotein lipase by forming complexes with angiopoietin-like protein 8 (ANGPTL-8), while glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1 (GPIHBP-1) facilitates the transfer of lipoprotein lipase to the luminal side of the endothelium, thereby increasing its catalytic activity to hydrolyze plasma triglycerides [10,12].

In addition to triglyceride-rich lipoproteins, high concentrations of lipoprotein a (Lp(a)) make up a considerable proportion of the residual cardiovascular risk. This statement is based on very solid genetic evidence from Mendelian randomization studies as the plasma concentration of this small lipoprotein is highly heritable [14–16].

Moreover, the lipoprotein particle distribution has been associated with cardiovascular risk [1,17]. In this respect, a high concentration of small dense LDL particles abundant in diabetic dyslipidemia is considered atherogenic as they can easily penetrate the endothelium to be deposited in the subintimal space [18–20]. On the other hand, high concentrations of small high-density lipoprotein (HDL) particles are considered especially protective as they are considered effective vehicles for reverse cholesterol transport [21,22].

The effects of novel proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies on LDL cholesterol and cardiovascular event reduction have thoroughly been investigated [23,24]. However, less evidence is available on the effects of PCSK9 antibodies on triglyceride metabolism and lipoprotein particle concentrations.

Therefore, the present study aimed to evaluate in detail the effects of the fully human PCSK9 antibody alirocumab on triglyceride-rich lipoproteins and lipoprotein particle subfractions. Moreover, the objective was to test the effects of treatment with alirocumab on lipoprotein lipase regulators. To answer these questions, we performed standardized fat-tolerance tests, nuclear magnetic resonance spectroscopy, lipoprotein analysis using a combined ultracentrifugation precipitation method, and enzyme-linked immunosorbent assays.

2. Methods

2.1. Study Design

The ALIROCKS study (NCT03559309) is a monocentric, longitudinal pilot study with 24 patients scheduled for treatment with alirocumab. Treatment with alirocumab was initiated based on the current guidelines for the treatment of dyslipidemia of the European
Atherosclerosis Society and the European Society of Cardiology [25]. Inclusion criteria were atherosclerotic cardiovascular disease and elevated LDL cholesterol despite maximum tolerated oral lipid-lowering therapy. Exclusion criteria were age < 18 years, pregnancy, and previous treatment with PCSK9 antibodies. There were 2 visits at the study site, the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Diagnostic procedures of the first visit included a physical examination and a questionnaire on the medical history. Laboratory and fat-tolerance testing were performed at the first and second visit. Predefined secondary outcome measures included changes in lipoprotein particle distribution, composition, and post-prandial lipemia, in response to treatment with alirocumab. The clinical trial was conducted in accordance with the Declaration of Helsinki and was approved by the Austrian Federal Office for Safety in Health Care (EudraCT: 2018-000981-12) and the Ethics Committee of the Medical University of Graz (protocol number: 29-519 ex 16/17, approval date: 6 April 2018). All participants gave written informed consent.

2.2. Clinical Characterization

Information on demographics, clinical characteristics, and lipid medication was collected at inclusion in the study. Familial hypercholesterolemia was documented according to medical history. Patients not receiving high-intensity statins defined as ≥40 mg atorvastatin or ≥20 mg rosvuastatin at baseline were categorized as having partial or complete statin intolerance.

2.3. Fat-Tolerance Test

The Lipotest® standardized meal was used for the fat-tolerance tests (D. GENOMERES Advanced Medical Research, Athens, Greece). It is a diagnostic meal with a special medical purpose, characterized as “food for specialized diagnostic determination of postprandial triglycerides”, and consists of 832 kcal total energy, comprising 75 g saturated fat, 25 g carbohydrates, 10 g protein, 2.1 g fiber, and 0.15 g salt [26]. The Lipotest® meal was provided to the study center in a sachet and comprised 115 g powder that was rehydrated by adding 150 mL water. The water was poured in an adequate bowl first; afterwards, the powder of the sachet was added to the water and mixed with a hand mixer or a whisk until the powder was completely dissolved and became a homogenous drink. The patients were advised to fast for at least 10 h before the test. Laboratory testing was performed before the test meal and two and four hours after the test meal. LDL cholesterol during the fat-tolerance tests was measured by lipoprotein electrophoresis at T = 0 (0 h) and calculated according to the Friedewald equation at 2 and 4 h [27].

2.4. Lipoprotein Analysis by Ultracentrifugation and Precipitation

Lipoprotein particles were separated using a combined ultracentrifugation precipitation method [28–30]. Plasma was ultracentrifuged at a density of d = 1.0063 kg/L, at 30,000 rpm for 18 h. The very low-density lipoprotein (VLDL) particle fraction was removed, and LDL were precipitated with phosphotungstic acid/MgCl₂. Cholesterol and triglycerides were measured using enzymatic reagents from Diasys (Holzheim, Germany) and were calibrated using secondary standards from Roche Diagnostics (Mannheim, Germany). Apolipoproteins (Apo), ApoB in VLDL and LDL, and Lp(a) were determined by immunoturbidimetry using reagents from DiaSys (Holzheim, Germany) and standards from Siemens (Marburg, Germany; ApoAI, ApoB, ApoE), Kamiya Biomedical (Seattle, WA, USA; ApoAII, ApoCII, ApoCIII), and Diasys (Lp(a)). The coefficients of variation were <5% [31].

2.5. Enzyme-Linked Immunosorbent Assays

ANGPTL-3 (ID: JP27750) and ANGPTL-4 (ID: JP27749) were measured with reagents from IBL (Minneapolis, MN, USA), GPIHBP-1 from TECAN (Männedorf, Switzerland, ID: 30131804), and circulating PCSK9 from Bio-Techne (Minneapolis, MN, USA, ID: DPC900).
The PCSK9 assay measured total plasma PCSK9 irrespective of binding to the antibody alirocumab.

2.6. Nuclear Magnetic Resonance Spectroscopy

Analyses of lipoprotein particle subclasses were performed using the AXINON® lipoFIT® nuclear magnetic resonance assay (Numares, Regensburg, Germany) with an Avance III HD nuclear magnetic resonance spectrometer (Bruker; Billerica, MA, USA), an Ascend 600 MHz magnet (Bruker), and using TopSpin 3.2 (Bruker) and Axinon Suite 1.0.0.1 (Numares, Regensburg, Germany) software. The lipoprotein sizes were 50-240 nm for large VLDL particles (L-VLDLp), 21.2-23 nm for large LDL particles (L-LDLp), 18-21.2 nm for small LDL particles (S-LDLp), 8.8-13 nm for large HDL particles (L-HDLp), and 7.3-8.8 nm for small HDL particles (S-HDLp). Total and small VLDL particle concentrations are not provided by the Numares method (AXINON® lipoFIT® nuclear magnetic resonance assay, Supplementary Materials) [32].

2.7. Statistical Analysis

The statistical design of this pilot trial was explorative and descriptive. The baseline characteristics are specified as numbers (percentages) in cases of categorical variables and as means (standard deviations) in cases of continuous variables. The area under the curve (AUC) analysis concerning the fat-tolerance testing was calculated by the trapezoid approximation (AUC(T0−4) = AUC(T0−2) + AUC(T2−4); AUC(T0−2) = (Value(T0) + Value(T2))/2 × (Time(T2)−Time(T0)), AUC(T2−4) = (Value(T2) + Value(T4))/2 × (Time(T4)−Time(T2)). Changes between baseline and week 10 were tested with the paired-samples t-test and/or related samples Wilcoxon signed rank test when Shapiro–Wilk analysis suggested non-parametric distribution. p-values ≤ 0.05 were considered significant. The SPSS 26.0 statistical program was used (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Study Population

The recruitment of the 24 participants was performed from 20 June 2018 to 30 January 2020 (Tables S1 and S2). Approximately 80% of the participants received 75 mg of alirocumab every two weeks and 20% received 150 mg alirocumab every two weeks. Two patients only received alirocumab injections twice, at baseline and at week 2. The reasons for their non-adherence were documented as drug access and communication barriers. Four patients had minor changes in their oral lipid-lowering therapies during the trial. Among these, two patients stopped their red yeast rice product, one stopped ezetimibe, and another one reduced their oral combination therapy from 80 mg atorvastatin plus 10 mg ezetimibe to 20 mg atorvastatin monotherapy. Due to the COVID-19 pandemic and the subsequent implementation of national countermeasures restricting all hospital visits to essential interventions only, the clinical trial had to be terminated before the last three participants had completed the study. Hence, 19 patients completed the trial (Table 1). The mean (standard deviation) treatment duration with alirocumab for participants who had completed the trial was 10.0 (0.7) weeks.
Table 1. Characteristics of trial participants (trial completion).

| Characteristic                          | Alirocumab (N = 19) |
|----------------------------------------|---------------------|
| Age—year                               | 66 (9)              |
| Female sex—n (%)                       | 9 (47.4)            |
| Male sex—n (%)                         | 10 (52.6)           |
| Smoker b—n (%)                         | 9 (47.4)            |
| Current Smoker b—n (%)                 | 4 (21.1)            |
| Concomitant Diseases—n (%)             | 19 (100)            |
| Cardiovascular Disease                 |                     |
| a. Coronary Heart Disease              |                     |
| b. Periperal Artery Disease            |                     |
| c. Cerebral Artery Disease             |                     |
| Chronic Kidney Disease                 | 4 (21.1)            |
| Familial Hypercholesterolemia d        | 2 (10.5)            |
| Adiposity                              | 4 (21.1)            |
| Type-2 Diabetes Mellitus               | 4 (21.1)            |
| Type-1 Diabetes Mellitus               | 0 (0)               |
| Hypertension                           | 15 (78.9)           |
| Number of prior Cardiovascular Events  |                     |
| Three                                  | 2 (10.5)            |
| Two                                    | 5 (26.3)            |
| One                                    | 9 (47.4)            |
| Zero                                   | 3 (15.8)            |
| Concomitant Lipid Medication—n (%)     |                     |
| High-Intensity Statins                  | 3 (15.8)            |
| Statins                                 | 5 (26.3)            |
| Ezetimibe                               | 13 (68.4)           |
| Dietary Supplements                     | 5 (26.3)            |
| Statin Intolerance h                    | 16 (84.2)           |

Legend: Values are numbers (percentages) or means (standard deviations) for categorical and continuous variables, respectively. a Current or former smoker. b Documented as current smoker or no stop date documented. c Confirmed by cardiac computed tomography but without documentation of prior cardiovascular event (e.g., stroke, myocardial infarction, or percutaneous intervention). d According to medical records. e Documented as stent, balloon, coronary artery bypass graft, myocardial infarction, or percutaneous intervention, prior strokes/transient ischemic attacks. f Documented as ≥40 mg of atorvastatin or ≥20 mg of rosuvastatin. g Exclusively red yeast rice combination products (monacolin K). h Patients that did not receive high-intensity statins at baseline (includes partial or complete intolerance).

3.2. Characteristics of Trial Participants

The cohort included middle-aged and elderly females and males. All 19 participants had documented coronary artery disease. Among these, seven patients had poly-vascular disease with an additional diagnosis of cerebral and/or peripheral artery disease. The vast majority, 16 participants, had received coronary intervention or bypass surgery. All three patients without prior coronary intervention or surgery had poly-vascular disease with coronary stenosis (50%) confirmed by cardiac computed tomography and carotid artery occlusive disease. One of the three patients without prior coronary intervention or surgery also had peripheral artery disease. Familial hypercholesterolemia was documented in two patients, and type-2 diabetes mellitus in four patients. A total of 16 study participants had partial or complete statin intolerance. Hence, very few participants received high-intensity statins at baseline. However, the proportion of patients taking ezetimibe as concomitant medication was high (Tables 1 and S2).

There was a significant positive association of baseline small dense LDL particles and triglyceride-rich large VLDL particles (r = 0.883, p < 0.001). Small and large LDL particles were not significantly correlated (r = 0.021, p = 0.932).
3.3. Effects of Alirocumab on Post-Prandial Lipemia

Fourteen subjects participated in the fat-tolerance testing. Triglycerides were significantly increased by the Lipotest® meal before and after 10 weeks of alirocumab treatment ($p < 0.001$). The relative increase in plasma triglycerides at 4 h versus t0 was approximately 25%. There was no effect of alirocumab on the post-prandial triglyceride response comparing changes in triglycerides (t4–t0) before and after alirocumab treatment ($p = 0.446$) or comparing the respective areas under the curve ($p = 0.485$, Figure 1 and Figure S1). Total, HDL, and non-HDL cholesterol remained unchanged during the fat-tolerance test.

![Figure 1. Fat-tolerance test results with Lipotest® meal at baseline and after 10 weeks of treatment with alirocumab. Legend: Triglyceride plasma levels at baseline and after 10 weeks of alirocumab treatment, before Lipotest® meal consumption (t0), at 2 h (t2), and 4 h (t4). Among the trial completion population, 14 patients participated in the per-protocol optional fat-tolerance assessment ($n = 14$). The small circles at the upper part of the figure identify outlier measurements. Outliers are defined as values between 1.5× and 3× interquartile ranges from the end of a box. Paired-samples $t$-test with two-sided $p$-value was performed.](image)

3.4. Effects of Alirocumab on Lipids and Lipoprotein Particles

There was an LDL cholesterol reduction of 69 mg/dL (−44%) in response to treatment with alirocumab. Cholesterol was reduced by 31%, ApoB by 40%, and Lp(a) by 14%. Two patients had documented familial hypercholesterolemia; in one of them, baseline LDL cholesterol was >300 mg/dL. Nine participants had Lp(a) values >50 mg/dL. In this subgroup, Lp(a) was reduced from 78 mg/dL to 68 mg/dL, resulting in a mean absolute reduction of 10 (10) mg/dL ($p = 0.021$). Alirocumab was also associated with a significant increase in HDL cholesterol of +17%. VLDL cholesterol did not change significantly, although a numerical reduction of 34% was observed (Table 2). Alirocumab treatment was associated with an increase in the VLDL triglycerides/VLDL ApoB ratio, which is considered a marker of VLDL size. Nuclear magnetic resonance analysis also suggested a modest increase in VLDL size but no change in the large VLDL particle.
concentration (Table 3 and Figure S2). There was a significant reduction in the total LDL particle concentration and a significant increase in total HDL particles. The decrease in the total LDL particle concentration was accounted for by a decrease in both large and small particles. The increase in the total HDL particle concentration was accounted for by an increase in buoyant HDL particles (Table 3 and Figure S3).

Table 2. Effects of alirocumab on lipids, lipoprotein particle subfractions, and lipoproteins.

| Parameters                              | Baseline | Week 10 | Absolute Change (mg/dL) | ± SD | Relative Change (%) | p-Value |
|-----------------------------------------|----------|---------|-------------------------|------|---------------------|---------|
| Cholesterol (mg/dL)                     | 236      | 162     | −74                     | 42   | −31                 | <0.001  |
| Triglycerides (mg/dL)                   | 236      | 162     | −74                     | 42   | −31                 | <0.001  |
| Lp(a) (mg/dL)                           | 47       | 130     | −7                      | 8    | −14                 | 0.002   |
| ApoAI (mg/dL)                           | 154      | 164     | +10                     | 13   | +7                  | 0.002   |
| ApoAII (mg/dL)                          | 34       | 35      | +1                      | 4    | +2                  | 0.384   |
| ApoB (mg/dL)                            | 110      | 66      | −44                     | 23   | −40                 | <0.001  |
| ApoCIII (mg/dL)                         | 14       | 14      | −1                      | 3    | −5                  | 0.411   |
| ApoE (mg/dL)                            | 12       | 9       | −3                      | 3    | −21                 | 0.001   |
| VLDL Cholesterol (mg/dL)                | 35       | 23      | −12                     | 41   | −34                 | 0.219   |
| VLDL Triglycerides (mg/dL)              | 35       | 23      | −12                     | 41   | −34                 | 0.219   |
| VLDL ApoB (mg/dL)                       | 15       | 10      | −5                      | 10   | −32                 | 0.046   |
| LDL Cholesterol (mg/dL)                 | 158      | 89      | −69                     | 63   | −44                 | <0.001  |
| LDL Triglycerides (mg/dL)               | 36       | 24      | −11                     | 7    | −32                 | <0.001  |
| LDL ApoB (mg/dL)                        | 95       | 56      | −39                     | 27   | −41                 | <0.001  |
| HDL Cholesterol (mg/dL)                 | 42       | 49      | +7                      | 7    | +17                 | <0.001  |
| HDL Triglycerides (mg/dL)               | 13       | 14      | +1                      | 2    | +9                  | 0.055   |

Legend: Shows lipoprotein analysis results by ultracentrifugation and precipitation method at baseline and after 10 weeks of alirocumab treatment. Trial completion population (n = 19). SD: Standard deviation; Mean values; Paired-samples t-test with two-sided p-value.

Table 3. Effects of alirocumab on lipoprotein particle numbers, ratios of particle subfractions, and lipoprotein lipase regulators.

| Parameters                              | Baseline | Week 10 | Absolute Change | ± SD | Relative Change (%) | p-Value |
|-----------------------------------------|----------|---------|-----------------|------|---------------------|---------|
| Lipoprotein Particle Number            |          |         |                 |      |                     |         |
| L-VLDLp (nmol/L)                        | 6.5      | 6.9     | +0.4            | 5.6  | +6                  | 0.752   |
| LDLp (nmol/L)                           | 1573     | 930     | −643            | 317  | −41                 | <0.001  |
| L-LDLp (nmol/L)                         | 832      | 498     | −335            | 454  | −40                 | 0.005   |
| S-LDLp (nmol/L)                         | 741      | 448     | −293            | 301  | −40                 | <0.001  |
| HDLp (nmol/L)                           | 32,391   | 34,585  | +2194           | 2294 | +7                  | 0.001   |
| L-HDLp (nmol/L)                         | 4758     | 6083    | +1325           | 1382 | +28                 | 0.001   |
| S-HDLp (nmol/L)                         | 28,436   | 28,940  | −593            | 2122 | +2                  | 0.252   |
| Lipoprotein Particle Size              |          |         |                 |      |                     |         |
| VLDL size (nm)                          | 49       | 52      | +3              | 5    | +6                  | 0.031   |
| LDL size (nm)                           | 21       | 21      | 0               | 0.5  | 0                   | 0.159   |
| HDL size (nm)                           | 8.8      | 9.0     | +0.2            | 0.2  | +2.3                | <0.001  |
| Ratios of Lipoprotein Particles        |          |         |                 |      |                     |         |
| Triglycerides/ApoB                      | 1.3      | 2.2     | +0.9            | 0.8  | +69                 | <0.001  |
| VLDL Triglycerides/ApoB                 | 0.9      | 1.6     | +0.7            | 0.8  | +78                 | 0.001   |
| VLDL Triglycerides/VLDL-ApoB            | 6.9      | 9.7     | +2.8            | 2.8  | +41                 | <0.001  |
| Cholesterol/ApoB                        | 2.2      | 2.6     | +0.5            | 0.3  | +18                 | <0.001  |
3.5. Effects of Alirocumab on Lipoprotein Lipase Regulators and Circulating PCSK9

Lipoprotein lipase-regulating proteins did not change in response to treatment with alirocumab (Tables 2 and 3). All patients with self-reported adherence showed a more than three-fold increase in circulating PCSK9 compared with their baseline examination. The plasma PCSK9 level increased from 0.25 to 2.24 µg/mL in the trial completion population, resulting in a mean change of +1.99 µg/mL (SD ± 0.68; p < 0.001; n = 19). The two non-adherent patients did not show an increase in circulating PCSK9 (<2-fold) and there was no LDL cholesterol reduction. Their PCSK9 levels remained <0.4 µg/mL, whereas, for all other adherent patients, these ranged between 1.1 and 3.8 µg/mL on alirocumab treatment. Among those participants with self-reported adherence, two patients did not show the expected decrease in LDL cholesterol, reflecting low/non-response to alirocumab treatment, but both had a 10- to 12-fold PCSK9 increase (Figure 2 and Figure S4, Table S3).

Figure 2. Plasma PCSK9 increase per patient in response to alirocumab treatment. Legend: The figure includes the 19 adherent patients and 2 non-adherent (NA) patients that did not receive alirocumab beyond week 2 (n = 21). The used enzyme-linked immunosorbent assay measured total plasma PCSK9 levels, and thus did not differentiate between bound and unbound PCSK9.
4. Discussion

The main finding of this pre-specified analysis of the ALIROCKS trial was that triglyceride metabolism was hardly affected by alirocumab treatment in patients with atherosclerosis and hypercholesterolemia. Fat-tolerance testing did not reveal significant effects of alirocumab on post-prandial lipemia. Proteins regulating triglyceride-rich lipoprotein metabolism, such as ApoCII, ApoCIII, GPIHBP-1, ANGPTL-3, and ANGPTL-4, remained unchanged. This supports the hypothesis that PCSK9 does not have strong effects on lipoprotein lipase. We could only detect a modest, non-significant reduction in fasting plasma triglycerides of 10%. This result is consistent with findings of a large, pooled analysis of 10 phase III alirocumab trials with 4983 participants, also reporting a modest triglyceride reduction of approximately 15% [33]. The pooled analysis also suggested that the triglyceride-lowering effect of alirocumab treatment is independent of a metabolic syndrome. However, patients with diabetes mellitus were excluded from this pooled analysis. The patient characteristics of our clinical trial were consistent with a recently published “real-world” non-interventional alirocumab study in clinical routine [34]. Not surprisingly, the effects of PCSK9 antibodies on triglyceride metabolism are more pronounced in patients with insulin-dependent type-2 diabetes and mixed hyperlipidemia, as shown in the ODYSSEY DM-INSULIN study [35]. Another randomized placebo-controlled trial with 12 patients with insulin-dependent type-2 diabetes mellitus also reported that alirocumab treatment reduced both fasting and post-prandial plasma triglycerides [36]. Similar reductions in post-prandial lipemia were reported for the PCSK9 antibody evolocumab in a non-randomized trial with 15 participants suffering from type-2 diabetes [37].

Another objective of the trial was to test the effects of alirocumab treatment on lipoprotein particles. Baseline small dense LDL particle and triglyceride-rich large VLDL particle concentrations showed a strong and positive association, reflecting the features of diabetic dyslipidemia [20]. There was no relevant positive correlation between small and large LDL particles, which is consistent with physiologic considerations and previous clinical studies, supporting the validity of the present nuclear magnetic resonance spectroscopy results [38]. Importantly, treatment with alirocumab was associated with a significant decrease in total, large, and small dense LDL particle concentrations. In contrast, the HDL particle concentration increased. These results are consistent with the findings of a post-hoc analysis of a randomized controlled phase 2 trial with 29 participants [39]. Of relevance, we also confirmed a previous study of our group with 350 participants wherein alirocumab treatment was suggested to be associated with an increase in VLDL size, which was estimated by an increased VLDL triglycerides/VLDL ApoB ratio, and a reduction in VLDL-associated apolipoproteins, suggesting higher clearance of small atherogenic VLDL remnant particles [31]. The present nuclear magnetic resonance spectroscopy data support this hypothesis regarding the increase in VLDL size.

We also observed a significant decrease in Lp(a), which may contribute to cardiovascular risk reduction beyond the beneficial effects of LDL cholesterol lowering, as recently suggested by a pre-specified analysis of the ODYSSEY OUTCOMES study [40]. Whether targeted Lp(a) lowering will reduce the cardiovascular event rate has yet to be demonstrated by an interventional outcome trial that is currently ongoing [41].

A very interesting but preliminary finding of the ALIROCKS study was that the total plasma concentration of PCSK9 may be a possible biomarker for adherence to treatment with PCSK9 antibodies. Circulating PCSK9 after treatment with PCSK9 antibodies comprises unbound PCSK9 and PCSK9 bound to PCSK9 antibodies. The immunoassay used in the ALIROCKS trial does not differentiate between antibody-bound or -unbound PCSK9. In the entire ALIROCKS cohort, total circulating PCSK9 markedly increased in response to alirocumab treatment, most likely due to a strong increase in PCSK9 bound to alirocumab. This finding agrees with the results from a recent study of our group [42]. Of note, two patients only received alirocumab twice and consequently showed neither a reduction in LDL cholesterol nor an increase in circulating PCSK9 at week 10. On the other hand, all patients adherent to alirocumab treatment showed a more than three-fold increase in total
circulating PCSK9. Only those two trial participants with <25% LDL cholesterol reduction but with a more than three-fold increase in total circulating PCSK9 may be categorized as low- or non-responders. Therefore, measuring total plasma PCSK9 may be instrumental in categorizing patients with no or low LDL cholesterol reduction as non-adherent patients or non-responders (Table 4). Such adherence testing strategies are increasingly relevant in times of expensive medications and constrained healthcare budgets [43]. However, systematic and larger investigations are required to support or challenge this proposed concept.

Table 4. Proposed evaluation for PCSK9 antibody adherence.

| Responder  | Non-Responder | Non-Adherent |
|------------|---------------|--------------|
| LDL Cholesterol ↓ | Yes | No | No |
| PCSK9 ↑ (x3) | N.A. | Yes | No |

Legend: Proposed evaluation strategy for testing low- to non-responder versus non-adherence. Total circulating PCSK9 level may differentiate between non-responder and non-adherent. Suggested cut-off value is a >3-fold PCSK9 level increase from baseline. ↑ = Increase, ↓ = Decrease; N.A.: Not Applicable.

The major strength of the ALRIOCKS study is the very precise clinical and metabolic characterization of the study participants, including lipid-tolerance testing. The Lipotest® used in the ALRIOCKS study is the best-described, sole diagnostic meal worldwide in commercial form to date [15]. This is also the first clinical trial prospectively investigating the effects of alirocumab on lipoprotein subclass particle concentrations measured with nuclear magnetic resonance spectroscopy in a “real-world” setting.

The limitations of the ALRIOCKS trial include the lack of a control group. However, all participants had a medical indication for treatment with PCSK9 antibodies. Hence, it would have been unethical to withhold alirocumab from half of the participants. The relatively small sample size may also be regarded a weak point of the ALRIOCKS study. Hence, future, larger studies are encouraged to confirm or challenge the present preliminary results of this exploratory pilot study. Nevertheless, it is unlikely that a clinically relevant impact of short-term lipid-lowering therapy on post-prandial lipemia will be detected in patients without diabetic dyslipidemia considering the minor effect size in the present cohort.

In summary, we could not detect significant effects of alirocumab treatment on triglyceride metabolism or post-prandial lipemia in a patient population without metabolic or glycemic preselection. Remarkably, total circulating PCSK9 may be instrumental in differentiating PCSK9 antibody non-responders from non-adherent patients. Future studies are required to confirm the present preliminary results.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biomedicines10010193/s1, Figure S1. Area under the curve (AUC) of triglycerides during fat-tolerance testing (t = 0–4 hours) at baseline visit and after 10 weeks of alirocumab; Figure S2. Distribution of VLDL particle size and changes by alirocumab treatment; Figure S3. Distribution of small-dense LDL particles and changes by alirocumab treatment; Figure S4. Plasma PCSK9 levels at baseline and after 10 weeks of alirocumab treatment; Table S1. Study population and alirocumab dosage; Table S2. Characteristics of all recruited trial participants; Table S3. LDL cholesterol and PCSK9 plasma levels per patient.

Author Contributions: T.M. and G.S. designed the trial and wrote the study protocol, were responsible for regulatory authority and ethics committee approvals, documentation, statistical analysis, interpretation of data, and medical writing. D.R.L., A.B., K.M., H.S. (Harald Sourij) and H.T. were responsible for patient recruitment, patient anamnesis, and fat-tolerance testing. T.S. and H.S. (Hubert Scharnagl) performed laboratory measurements. W.M., G.R. and U.L. critically reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Medical University of Graz and by unrestricted grants from Numares AG and Sanofi-Aventis.
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Graz (protocol code: 29-519 ex 16/17 and date of approval: 6 April 2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on specific request from the corresponding author.

Acknowledgments: With thanks to the team of Numares AG for conducting the nuclear magnetic resonance spectroscopy, beyond their financial support of the trial. Special thanks to the Doctoral School of the Medical University of Graz for funding of laboratory assays.

Conflicts of Interest: The costs of this study were in part defrayed using research grants from Numares AG and Sanofi-Aventis. These commercial entities were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. T. Metzner is an employee of Sanofi-Aventis and performed the scientific work for this study in his role as a doctoral student at the Medical University of Graz, outside his work at Sanofi-Aventis. D. R. Leitner received personal fees from Sanofi-Aventis. H. Sourij has received research grants from Sanofi-Aventis, and personal fees from Amgen as well as Sanofi-Aventis as advisor and speaker. W. März reports grants and personal fees from Amgen, Sanofi-Aventis, and from Numares AG. H. Scharnagl has received grants and/or personal fees from Sanofi-Aventis, Amgen, and Numares AG. H. Toplak reports grants and personal fees from Sanofi-Aventis as advisor and speaker. G. Silbernagel reports grants and personal fees from Sanofi-Aventis, grants, personal fees, and non-financial support from Amgen, and grants from Numares AG. All authors declare no other competing interests.

References

1. Borén, J.; Chapman, M.J.; Krauss, R.M.; Packard, C.J.; Bentzon, J.F.; Binder, C.J.; Daemen, M.J.; Demer, L.L.; Hegele, R.A.; Nicholls, S.J.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* 2020, 41, 2313–2330. [CrossRef] [PubMed]

2. Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur. Heart J.* 2017, 38, 2495–2472. [CrossRef] [PubMed]

3. Ference, B.A.; Graham, I.; Tokgozoglu, L.; Catapano, A.L. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. *J. Am. Coll. Cardiol.* 2018, 72, 1141–1156. [CrossRef] [PubMed]

4. Sampson, U.K.; Fazio, S.; Linton, M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges. *Curr. Atheroscler. Rep.* 2012, 14, 1–10. [CrossRef] [PubMed]

5. Nordestgaard, B.G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology. *Circ. Res.* 2016, 118, 547–563. [CrossRef]

6. Ference, B.A.; Kastelein, J.J.P.; Catapano, A.L. Lipids and Lipoproteins in 2020. *JAMA* 2020, 324, 595–596. [CrossRef] [PubMed]

7. Packard, C.J.; Boren, J.; Taskinen, M.R. Causes and Consequences of Hypertriglyceridemia. *Front. Endocrinol.* 2020, 11, 252. [CrossRef]

8. Kim, N.H.; Kim, S.G. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. *Diabetes Metab. J.* 2020, 44, 213–221. [CrossRef] [PubMed]

9. Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T., Jr.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N. Engl. J. Med.* 2019, 380, 11–22. [CrossRef] [PubMed]

10. Ruscica, M.; Zimetti, F.; Adorni, M.P.; Sirtori, C.R.; Lupo, M.G.; Ferri, N. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. *Pharmacol. Res.* 2020, 153, 104653. [CrossRef] [PubMed]

11. Rocha, N.A.; East, C.; Zhang, J.; McCullough, P.A. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. *Curr. Atheroscler. Rep.* 2017, 19, 62. [CrossRef]

12. Chait, A.; Eckel, R.H. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. *Ann. Intern. Med.* 2019, 170, 626–634. [CrossRef]

13. Wolska, A.; Remund, M.; Remaley, A.T. Apolipoprotein C-II: The re-emergence of a forgotten factor. *Curr. Opin. Lipidol.* 2020, 31, 147–153. [CrossRef] [PubMed]
14. Burgess, S.; Ference, B.; Staley, J.; Freitag, D.F.; Mason, A.; Nielsen, S.F.; Willeit, P.; Young, R.; Surendran, P.; Karthikeyan, S.; et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. *JAMA Cardiol.* 2018, 3, 619–627. [CrossRef] [PubMed]

15. Langsted, A.; Nordestgaard, B.G. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. *Curr. Atheroscler. Rep.* 2021, 23, 46. [CrossRef] [PubMed]

16. Nordestgaard, B.G.; Langsted, A. Lipoprotein(a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. *J. Lipid Res.* 2016, 57, 1953–1975. [CrossRef]

17. Koba, S.; Hirano, T.; Kondo, T.; Shibata, M.; Suzuki, H.; Murakami, M.; Geshi, E.; Katagiri, T. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. *Am. Heart J.* 2002, 144, 1026–1035. [CrossRef]

18. Meeusen, J.W. Is Small Dense LDL a Highly Atherogenic Lipid or a Biomarker of Pro-Atherogenic Phenotype? *Clin. Chem.* 2021, 67, 927–928. [CrossRef]

19. Hoogeveen, R.C.; Gaubatz, J.W.; Sun, W.; Dodge, R.; Crosby, J.; Jiang, J.; Couper, D.; Virani, S.S.; Kathiresan, S.; Boerwinkle, E.; et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk In Communities (ARIC) study. *Arterioscler. Thromb. Vasc. Biol.* 2014, 34, 1069–1077. [CrossRef]

20. Krauss, R.M. Lipids and lipoproteins in patients with type 2 diabetes. *Diabetes Care* 2004, 27, 1496–1504. [CrossRef]

21. März, W.; Kleber, M.E.; Scharnagl, H.; Speer, T.; Zewinger, S.; Ritsch, A.; Parhofer, K.G.; Von Eckardstein, A.; Landmesser, U.; Laufs, U. HDL cholesterol: Reappraisal of its clinical relevance. *Clin. Res. Cardiol.* 2017, 106, 663–675. [CrossRef]

22. Silbernagel, G.; Zagel, P.; Pfahler, V.; Genser, B.; Scharnagl, H.; Kleber, M.E.; Delgado, G.; Ohrui, H.; Ritsch, A.; Grammer, T.B.; et al. High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality. *Clin. Chem.* 2017, 63, 1886–1896. [CrossRef]

23. Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N. Engl. J. Med.* 2018, 379, 2097–2107. [CrossRef]

24. Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.* 2017, 376, 1713–1722. [CrossRef]

25. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Eur. Heart J.* 2020, 41, 111–188. [CrossRef]

26. Tentolouris, N.; Kanellos, P.T.; Siami, E.; Athanasopoulou, E.; Chaviaras, N.; Kolovou, G.; Sfikakis, P.P.; Katsilambros, N. Assessment of the Validity and Reproducibility of a Novel Standardized Test Meal for the Study of Postprandial Triacylglycerol Concentrations. *Lipids* 2017, 52, 679–686. [CrossRef]

27. Friedewald, W.T.; Levy, R.I.; Wissler, W. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* 1972, 18, 499–502. [CrossRef] [PubMed]

28. Wanner, C.; Horl, W.H.; Luley, C.H.; Wieland, H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. *Kidney Int.* 1991, 39, 754–760. [CrossRef] [PubMed]

29. Bachorik, P.S.; Ross, J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. *Clin. Chem.* 1995, 41, 1414–1420. [CrossRef] [PubMed]

30. Silbernagel, G.; Scharnagl, H.; Kleber, M.E.; Delgado, G.; Stojakovic, T.; Laaksenon, R.; Erdmann, J.; Rankinen, T.; Bouchard, C.; Landmesser, U.; et al. LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. *Atherosclerosis* 2019, 282, 37–44. [CrossRef]

31. Hollstein, T.; Vogt, A.; Brenkowitz, T.; Stojakovic, T.; März, W.; Laufs, U.; Böilukbasi, B.; Steinhagen-Thiessen, E.; Scharnagl, H.; Kassner, U. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. *Vasc. Pharmacol.* 2019, 116, 8–15. [CrossRef] [PubMed]

32. Needham, L.L.; Smy, L.; Lee, M.A.; Kunzler, T.M.; Genzen, J.R. Phlebotomy tube interference with nuclear magnetic resonance (NMR) lipoprotein subclass analysis. *Clin. Chim. Acta* 2018, 488, 235–241. [CrossRef]

33. Henry, R.R.; Müller-Wieland, D.; Taub, P.R.; Bujas-Bobanovic, M.; Louie, M.J.; Letierce, A.; Ginsberg, H.N. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. *Diabetes Obes. Metab.* 2018, 20, 1632–1641. [CrossRef]

34. Leitner, D.R.; Toplak, H.; Kedenko, L.; Steinmaurer, T.; Gräff, V.; Metzner, T.; Schweiger, E.M.; Prager, R. Efficacy and tolerability of alirocumab in Austrian clinical practice—Results of the non-interventional PEARL-AT study. *Curr. Med Res. Opin.* 2020, 36, 1419–1425. [CrossRef] [PubMed]

35. Ray, K.K.; Del Prato, S.; Müller-Wieland, D.; Cariou, B.; Colhoun, H.M.; Tinahones, F.J.; Domenger, C.; Letierce, A.; Mandel, J.; Samuel, R.; et al. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: Analysis of the ODYSSEY DM-DYSPLIPIDEMIA and DM-INSULIN studies. *Cardiovasc. Diabetol.* 2019, 18, 149. [CrossRef] [PubMed]
36. Burggraaf, B.; Pouw, N.M.; Fernández-Arroyo, S.; Zee, L.C.V.V.-D.; Van De Geijn, G.M.; Birnie, E.; Msc, J.H.; Van Der Zwan, E.M.; Mulder, M.T.; Rensen, P.C.; et al. A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus. *Diabetes Obes. Metab.* 2020, 22, 807–816. [CrossRef]

37. Taskinen, M.-R.; Björnson, E.; Andersson, L.; Kahri, J.; Porthan, K.; Matikainen, N.; Söderlund, S.; Pietiläinen, K.; Hakkarainen, A.; Lundbom, N.; et al. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. *J. Clin. Lipidol.* 2020, 14, 77–87. [CrossRef]

38. Williams, P.T.; Zhao, X.-Q.; Marcovina, S.M.; Otvos, J.D.; Brown, B.G.; Krauss, R.M. Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. *Atherosclerosis* 2014, 233, 713–720. [CrossRef]

39. Koren, M.J.; Kereiakes, D.; Pourfarzib, R.; Winegar, D.; Banerjee, P.; Hamon, S.; Hanotin, C.; McKenney, J.M. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. *J. Am. Heart Assoc.* 2015, 4. [CrossRef]

40. Bittner, V.A.; Szarek, M.; Aylward, P.E.; Bhatt, D.L.; Diaz, R.; Edelberg, J.M.; Fras, Z.; Goodman, S.G.; Halvorsen, S.; Hanotin, C.; et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. *J. Am. Coll. Cardiol.* 2020, 75, 133–144. [CrossRef]

41. Tsimikas, S.; Moriarty, P.M.; Stroes, E.S. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. *J. Am. Coll. Cardiol.* 2021, 77, 1576–1589. [CrossRef] [PubMed]

42. Silbernagel, G.; Steiner, L.K.; Hollstein, T.; Fauler, G.; Scharnagl, H.; Stojakovic, T.; Schumann, F.; Bölükbası, B.; März, W.; Steinhagen-Thiessen, E.; et al. The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. *J. Lipid Res.* 2019, 60, 161–167. [CrossRef] [PubMed]

43. Drexel, H.; Coats, A.J.S.; Spoletini, I.; Bilato, C.; Mollace, V.; Perrone-Filardi, P.; Rosano, G.M.C. ESC position paper on statins adherence and implementation of new lipid-lowering medications: Barriers to be overcome. *Eur. Heart J. Cardiovasc. Pharmacother.* 2020, 6, 115–121. [CrossRef] [PubMed]